SCHEMBL6097350

SCHEMBL6097350

COC(=O)C1(S(=O)(=O)N2CCC(Oc3ccc(C(F)(F)F)cc3)CC2)CCN(c2ncccn2)CC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP13 P45452 6/20 0.47
MMP2 P08253 5/20 0.47
FPR2 P25090 1/20 0.44
PROKR1 Q8TCW9 1/20 0.44
SCN9A Q15858 2/20 0.44
KCNH2 Q12809 1/20 0.44
SCN5A Q14524 1/20 0.44
MMP12 P39900 1/20 0.43
LIPE Q05469 1/20 0.41
EPHX2 P34913 1/20 0.41
CCR6 P51684 1/20 0.40
MMP3 P08254 1/20 0.40
MMP9 P14780 1/20 0.40
MMP8 P22894 1/20 0.40
MMP14 P50281 1/20 0.40
SLC6A7 Q99884 1/20 0.39
TEAD1 P28347 1/20 0.39
ACACB O00763 1/20 0.38
USP2 O75604 2/20 0.38
CYP3A4 P08684 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6095298 0.91 ACACB (0.49) MMP13MMP2FPR2PROKR1SCN9A
SCHEMBL6095160 0.90 MMP13 (0.47) MMP13MMP2FPR2PROKR1SCN9A
SCHEMBL6097326 0.90 MMP13 (0.51) MMP13MMP2FPR2PROKR1SCN9A
SCHEMBL6098087 0.89 GPR119 (0.43) MMP13MMP2FPR2PROKR1SCN9A
SCHEMBL6099484 0.83 MMP13 (0.49) MMP13MMP2FPR2PROKR1MMP12
SCHEMBL6097003 0.82 MMP13 (0.41) MMP13MMP2FPR2PROKR1SCN9A
SCHEMBL6097858 0.82 ADRB2 (0.49) MMP13MMP2KCNH2MMP12LIPE
SCHEMBL6099760 0.81 MMP13 (0.48) MMP13MMP2FPR2PROKR1KCNH2
SCHEMBL6095614 0.81 ACACB (0.47) MMP13MMP2FPR2PROKR1SCN9A
SCHEMBL6094513 0.81 MMP2 (0.48) MMP13MMP2FPR2PROKR1SCN9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7067670-B2 Sulfamato hydroxamic acid metalloprotease inhibitor WARNER LAMBERT COMPANY (US) 2006-06-27 US disclosed
US-20050049280-A1 Sulfamato hydroxamic acid metalloprotease inhibitor PHARMACIA CORPORATION 2005-03-03 US disclosed
US-6800646-B1 Sulfamato hydroxamic acid metalloprotease inhibitor PHARMACIA CORPORATION 2004-10-05 US disclosed
US-6492367-B1 Sulfamato hydroxamic acid metalloprotease inhibitor G. D. SEARLE & COMPANY 2002-12-10 US disclosed
US-6448250-B1 INHIBITS THE ACTIVITY OF ONE OR MORE OF THE FOLLOWING MATRIX METALLOPROTEINASES: MMP-2, MMP-9, AND MMP-13, WHILE EXHIBITING SUBSTANTIALLY LESS INHIBITORY ACTIVITY AGAINST MMP-1 G. D. SEARLE & COMPANY 2002-09-10 US disclosed
EP-1157021-A1 SULFAMATO HYDROXAMIC ACID METALLOPROTEASE INHIBITOR G.D. SEARLE & CO. (US) 2001-11-28 EP disclosed
WO-2000046221-A1 SULFAMATO HYDROXAMIC ACID METALLOPROTEASE INHIBITOR G.D. SEARLE & CO. (US) 2000-08-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050049280-A1 Sulfamato hydroxamic acid metalloprotease inhibitor MMP14, MMP12, MMP17 MMP13 23/4885MMP2 8/4885FPR2 2242/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.